Niharika B Mettu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Mesenchymal Stem Cells

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew L Coveler, Matthew J Reilley, Mark M Zalupski, Teresa Macarulla, Christos Fountzilas, Mariano Ponz-Sarvisé, Adnan Nagrial, Nataliya V Uboha, Sophia Frentzas, Michael James Overman, Anne M Noonan, Wells A Messersmith, Nick Pavlakis, Niharika B Mettu, Ina Bisha, Ying Wang, Paul Smith, Elina Murtomaki, Agata A Bielska, Veronique Bragulat, Zachary A Cooper, Rakesh Kumar, David R Spigel
A Phase 1b/2 Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Ezra Y Rosen, Timothy Anthony Yap, Elizabeth K Lee, Martin Højgaard, Niharika B Mettu, Stéphanie Lheureux, Benedito Arruda Carneiro, Ruth Plummer, Adrian J Fretland, Danielle Ulanet, Yi Xu, Robin McDougall, Maria Koehler, Elisa Fontana
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Camonsertib. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Pamela N Munster, Nicholas O Iannotti, Daniel C Cho, Joanne M Jeter, Liza C Villaruz, Geoffrey Thomas Gibney, Frank Stephen Hodi, Niharika B Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven J O'Day
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer research communications 3 (12) (2023)
Niharika B Mettu, Donna Niedzwiecki, Christel Rushing, Andrew B Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C Bendell, Hope Uronis
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. Cancer chemotherapy and pharmacology 83 (6) (2019)